Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 21, 2011; 17(43): 4779-4786
Published online Nov 21, 2011. doi: 10.3748/wjg.v17.i43.4779
Published online Nov 21, 2011. doi: 10.3748/wjg.v17.i43.4779
Table 1 Comparison of baseline clinicopathological characteristics between cetuximab-containing chemotherapy group and non-cetuximab-containing group n (%)
| Clinical factors | Total | Cetuximab chemotherapy | Non-cetuximab chemotherapy | P value |
| Gender | 0.85 | |||
| Male | 54 (63.5) | 29 (64.4) | 25 (62.5) | |
| Female | 31 (36.5) | 16 (35.6) | 15 (37.5) | |
| Age (yr), median (range) | 50 (12-79) | 0.56 | ||
| Risk group (40-60) | 46 (54.1) | 23 (51.1) | 23 (57.5) | |
| Non-riskgroup (< 40) | 39 (45.9) | 22 (48.9) | 17 (42.5) | |
| Family history of tumor | 0.63 | |||
| Yes | 12 (14.1) | 9 (20.0) | 3 (15.0) | |
| No | 73 (85.9) | 36 (80.0) | 17 (85.0) | |
| Tumor site | 0.89 | |||
| Rectum | 24 (28.2) | 13 (28.9) | 11 (27.5) | |
| Colon | 61 (71.8) | 32 (71.1) | 29 (72.5) | |
| Primary clinical stage | 0.86 | |||
| II | 12 (14.1) | 5 (11.1) | 7 (17.5) | |
| III | 25 (29.4) | 15 (33.3) | 10 (25.0) | |
| IV | 48 (56.5) | 25 (55.6) | 23 (57.5) | |
| Histological grade | 0.93 | |||
| Well differentiation | 6 (7.1) | 3 (6.7) | 3 (7.5) | |
| Moderate differentiation | 57 (67.1) | 30 (66.6) | 26 (65.0) | |
| Poor differentiation | 22 (25.9) | 12 (26.7) | 11 (27.5) |
- Citation: Guo GF, Jiang WQ, Zhang B, Cai YC, Xu RH, Chen XX, Wang F, Xia LP. Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer. World J Gastroenterol 2011; 17(43): 4779-4786
- URL: https://www.wjgnet.com/1007-9327/full/v17/i43/4779.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i43.4779